<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04325620</url>
  </required_header>
  <id_info>
    <org_study_id>HM-ESOM-302</org_study_id>
    <nct_id>NCT04325620</nct_id>
  </id_info>
  <brief_title>Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease</brief_title>
  <official_title>A Multicenter, Randomized, Parallel, Double-Blinded, Placebo-controlled Phase 3 Study to Compare Efficacy and Safety of HIP1601 in Patients With Non-Erosive Gastroesophageal Reflux Disease(NERD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and clinical efficacy of HIP1601 in
      patients with Non-erosive gastroesphageal reflux disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, Randomized, Parallel, Double-Blinded, Placebo-controlled Phase Ⅲ Study to
      Compare Efficacy and Safety of HIP1601 in Patients with Non-Erosive Gastroesophageal Reflux
      Disease(NERD)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">December 16, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 16, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with complete resolution of major symptoms at 4-week</measure>
    <time_frame>4 week</time_frame>
    <description>Complete resolution is defined as no episodes of symptom during the last 7 days of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with complete resolution of major symptoms at 2-week</measure>
    <time_frame>2 week</time_frame>
    <description>Complete resolution is defined as no episodes of symptom during the last 7 days of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of Reflux disease symptom assessment using Reflux Disease Questionnaire(RDQ)</measure>
    <time_frame>2, 4 week</time_frame>
    <description>RDQ frequncy and severity score is 0 to 5 point scale, high score mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete resolution of major symptoms</measure>
    <time_frame>4 week</time_frame>
    <description>defined as time to the first day of complete resolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution rate of major symptoms of first 7 days</measure>
    <time_frame>1 week</time_frame>
    <description>defined as first of 7 days with no episodes of symptom using subject's diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major symptoms-Free days</measure>
    <time_frame>1, 4 week</time_frame>
    <description>Major symptoms-Free days mean rate of days that symtom's severity score is '0' using subject's diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life assessment using Patient Assessment of upper Gastrointestinal disorders-Quality of Life(PAGI-QoL)</measure>
    <time_frame>4 week</time_frame>
    <description>PAGI-QoL total score is 0 to 30 point scale, high score mean a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of rescue medication amounts</measure>
    <time_frame>4 week</time_frame>
    <description>Use of rescue medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Non-erosive Gastroesphageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>HIP1601 Amg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will receive tretment of HIP1601 Amg, orally, once daily for 4weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HGP1805</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The participants will receive tretment of HGP1805(Placebo of HIP1601), orally, once daily for 4weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIP1601</intervention_name>
    <description>HIP1601</description>
    <arm_group_label>HIP1601 Amg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP1805</intervention_name>
    <description>Placebo of HIP1601</description>
    <arm_group_label>HGP1805</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19≤ age ≤ 75

          -  Patients who were not observed mucosal break('not present') according to the LA
             classification(LA grade) on the EGDEsophago-Gastro-Duodenoscopy

          -  Patients who had experienced major symptom within 3 months Patients experienced
             heartburn or acid regurgitation within 7 days of screening day

          -  Patients who had experienced major symptom within 7 days before randomization. Entry
             into study also required that patients had experienced at least mild symptoms on at
             least 2 days/week or at least moderate symptoms on at least 1 day/week based on RDQ

          -  Patients understood the consents and purpose of this trial and signed consent form

        Exclusion Criteria:

          -  Patients who have erosive GERD, Barrett's esophagus(other significant dysplasia of
             esophagus), gastroesophageal varicose veins, active peptic ulcer, gastrointestinal
             bleeding or malignant GI tumor confirmed by endoscopy

          -  Patients who have a history of gastric or gastroesophageal surgery

          -  Patients who have Zollinger-Ellison syndrome, eosinophilic esophagitis, primary
             esophageal motility disorder, acute upper gastrointestinal bleeding, Functional
             dyspepsia, IBS, IBD within 3 months before Visit 1

          -  Patients with clinically significant liver, kidney, nervous system, respiratory,
             endocrine, hematologic, cardiovascular, urinary system disease.

          -  Patients Has a severe liver disorder(AST or ALT level exceeds 3 times more than normal
             upper range at Visit 1)

          -  Has a clinically significant renal failure(MDRD eGFR ≤ 59 mL/min/1.73m2 or Serum
             creatinine &gt;2.0mg/dL at Visit 1)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jung Jin-A, Ph.D</last_name>
    <phone>(82)-2-410-9038</phone>
    <email>jajung@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Na-Young, MD, PhD</last_name>
      <phone>(82)-31-787-7008</phone>
      <email>nayoungkim49@empas.com</email>
    </contact>
    <investigator>
      <last_name>Kim Na-Young, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

